The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 19 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Teladoc Health Inc is $7.00, about 25.2% below its July 28 closing price of $9.36.
Full-year and third-quarter outlook
Teladoc Health sees full-year 2026 revenue between $2.36 bln and $2.45 bln.
The company expects BetterHelp segment revenue to decline 13% to 19% in 2026.
Teladoc Health anticipates 3Q 2026 revenue between $569 mln and $609 mln.
BetterHelp decline weighed on results
BetterHelp cash pay decline: the company said accelerated decline in BetterHelp cash pay revenue weighed on overall results.
Insurance demand and provider capacity: the company said stronger than anticipated demand for insurance-covered BetterHelp services outpaced available provider capacity, limiting revenue conversion.
Integrated Care growth: the Integrated Care segment posted modest revenue growth and improved adjusted EBITDA margin.
TDOC•
